Alixorexton vs Oveporexton
Comparison of Alixorexton (Moderate evidence) and Oveporexton (Moderate evidence).
Last updated: February 12, 2026
Alixorexton
Oveporexton
Overview
Alixorexton and Oveporexton are both studied in the peptide research space.
Alixorexton: An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1).
Oveporexton: A first-in-class oral orexin receptor 2 (OX2R) selective agonist developed by Takeda for narcolepsy type 1.
Evidence Comparison
| Aspect | Alixorexton | Oveporexton |
|---|---|---|
| Evidence Level | Moderate | Moderate |
| Human Studies | 12 | 22 |
| Preclinical Studies | 6 | 6 |
| Total Sources | 18 | 28 |
Key Differences
| Aspect | Alixorexton | Oveporexton |
|---|---|---|
| Category | Cognitive | Cognitive |
| Evidence Strength | Moderate | Moderate |
| Total Sources | 18 | 28 |
| Human Studies | 12 | 22 |
Summary
- Alixorexton: Moderate evidence with 18 total sources (12 human)
- Oveporexton: Moderate evidence with 28 total sources (22 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.